4,4,10,13,14-pentamethyl-17-(6-methylhept-5-en-2-yl)-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,15-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4,4,10,13,14-pentamethyl-17-(6-methylhept-5-en-2-yl)-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthrene-3,15-diol
• 化学式: C₃₀H₄₈O₂
• 分子量: 440.7
• InChiKey: CCFQLQIYEHITNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Method and composition for inhibiting virus infection
  申请人：ARJIL BIOTECH HOLDING COMPANY LIMITED

  公开号：US11253527B2

  公开（公告）日：2022-02-22

  The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.

  本发明涉及一种用于制备预防和/或治疗病毒感染（尤其是乙型肝炎病毒感染和/或单纯疱疹病毒感染）的药物组合物及其用途。
• METHOD AND COMPOSITION FOR INHIBITING VIRUS INFECTION
  申请人：ARJIL BIOTECH HOLDING COMPANY LIMITED

  公开号：US20200268771A1

  公开（公告）日：2020-08-27

  The present invention pertains to a composition for preparing a medicament for preventing and/or treating a virus infection, especially a hepatitis B virus infection and/or a herpes simplex virus, and uses thereof.
• METHOD AND COMPOSITION FOR REVERSING AND/OR INHIBITING ATHEROSCLEROSIS
  申请人：ARJIL BIOTECH HOLDING COMPANY LIMITED

  公开号：US20200330485A1

  公开（公告）日：2020-10-22

  The present invention pertains to a method for inhibiting, reducing or reversing atherosclerosis or a composition or pharmaceutical composition for preventing or treating an atherosclerotic disease containing a preparation of Antrodia camphorata , and/or one or more active compounds isolated form Antrodia camphorataa.
• COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF CORONAVIRUS INFECTIONS
  申请人：ARJIL BIOTECH HOLDING COMPANY LIMITED

  公开号：US20210338690A1

  公开（公告）日：2021-11-04

  The present invention pertains to anti-coronaviral compounds. The disclosure includes a method for preventing and/or treating a coronavirus infection through the inhibition of a cysteine protease in a virus, particularly SARS-COV-2. Also provided includes the composition/pharmaceutical composition for preventing and/or treating a coronavirus infection comprising any of the compounds, pharmaceutically acceptable salt thereof, or its mixture, and the use of the compounds.